IONS:NASDAQ, Ionis Pharmaceuticals, Inc.

IONS stock overview

Ionis Pharmaceuticals, Inc. (IONS:NASDAQ) closed at $39.42 on November 6, 2026, up 1.60% on the day. The stock trades 54.6% below its 52-week high of $86.74 and 2.9% above its 52-week low of $38.31. Over the past year, it lost 46.4%. Ionis Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $39.42
Day change: +1.60%
Volume: 2,911,470
Average volume: 3,187,409
Market cap: 6B+
52-week range: $38.31 – $86.74
50-day average: $46.80
200-day average: $65.82

Price action over the past year

In 252 trading sessions since November 6, 2025, IONS closed higher on 117 days (46%). Its best day was August 3, 2026 (+5.25%) and its worst was July 9, 2026 (-23.90%). The stock moved 10% or more in a single session 1 time.

Recent signals

Nov 6, 2026: Down 30.8% over 90 days, from $56.94 (Dips & Crashes scanner)
Nov 2, 2026: News catalyst: Earnings (News Catalysts scanner)

IONS news

Nov 7, 2026: Ionis Pharmaceuticals (IONS) Stock Still Looks Pricey Despite Pelacarsen Trial Failure
Nov 5, 2026: Curious about Ionis Pharmaceuticals (IONS) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Nov 3, 2026: Ionis Faces First Real Test Of Tringolza's Broad SHTG Launch As Shares Sit Near Lows
Nov 2, 2026: Ionis to hold third quarter 2026 financial results webcast
Nov 2, 2026: Should You Buy The Dip In Alnylam Stock?
Oct 30, 2026: What Just Happened To Alnylam Stock?
Oct 29, 2026: Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”
Oct 29, 2026: ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

About Ionis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...

Similar stocks

Find more stocks like IONS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.